VistaGen公布Fasedienol治疗社交焦虑障碍急性期Palisade-4三期公开演讲挑战试验的顶线及事后分析数据

美股速递
Jun 30

VistaGen Therapeutics, Inc. (VTGN) 公布了其候选药物Fasedienol用于社交焦虑障碍急性期治疗的三期临床试验Palisade-4的顶线数据及事后分析结果。该试验采用公开演讲挑战模型进行评估。

数据显示,在主要终点和关键次要终点上,Fasedienol治疗组与安慰剂组相比,未达到统计学显著性差异。然而,公司进行的探索性事后分析指出,在预先设定的亚组人群中观察到了具有临床意义的改善信号。

此次公布的数据为后续临床开发策略提供了重要参考。公司表示将继续深入分析完整数据集,以进一步明确Fasedienol的潜在治疗价值。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10